<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="case-report" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">JAAD Case Rep</journal-id><journal-id journal-id-type="iso-abbrev">JAAD Case Rep</journal-id><journal-title-group><journal-title>JAAD Case Reports</journal-title></journal-title-group><issn pub-type="epub">2352-5126</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">38125030</article-id><article-id pub-id-type="pmc">PMC10730335</article-id><article-id pub-id-type="pii">S2352-5126(23)00375-2</article-id><article-id pub-id-type="doi">10.1016/j.jdcr.2023.09.029</article-id><article-categories><subj-group subj-group-type="heading"><subject>Case Series</subject></subj-group></article-categories><title-group><article-title>Mohs micrographic surgery for treatment of non&#x02013;melanoma skin cancer involving the nipple-areola complex: A case series of 8 patients</article-title></title-group><contrib-group><contrib contrib-type="author" id="au1"><name><surname>Nowsheen</surname><given-names>Somaira</given-names></name><degrees>MD, PhD</degrees></contrib><contrib contrib-type="author" id="au2"><name><surname>Pousti</surname><given-names>Bobak</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="author" id="au3"><name><surname>Miller</surname><given-names>Adam</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="author" id="au4"><name><surname>Eichstadt</surname><given-names>Shaundra</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="author" id="au5"><name><surname>Brian Jiang</surname><given-names>Shang I.</given-names></name><degrees>MD</degrees><email>s2jiang@health.ucsd.edu</email><xref rid="cor1" ref-type="corresp">&#x02217;</xref></contrib><aff id="aff1">Department of Dermatology, University of California San Diego, San Diego, California</aff></contrib-group><author-notes><corresp id="cor1"><label>&#x02217;</label>Correspondence to: Shang I. Brian Jiang, MD, Dermatologic and Mohs Micrographic Surgery, University of California San Diego, 8899 University Center Lane, Suite 350, San Diego, CA 92122. <email>s2jiang@health.ucsd.edu</email></corresp></author-notes><pub-date pub-type="pmc-release"><day>10</day><month>10</month><year>2023</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="collection"><month>12</month><year>2023</year></pub-date><pub-date pub-type="epub"><day>10</day><month>10</month><year>2023</year></pub-date><volume>42</volume><fpage>122</fpage><lpage>125</lpage><permissions><copyright-statement>&#x000a9; 2023 by the American Academy of Dermatology, Inc. Published by Elsevier Inc.</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>American Academy of Dermatology, Inc.</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).</license-p></license></permissions><kwd-group id="kwrds0010"><title>Key words</title><kwd>areola</kwd><kwd>breast cancer</kwd><kwd>case series</kwd><kwd>dermatology</kwd><kwd>Mohs</kwd><kwd>nipple</kwd><kwd>retrospective review</kwd><kwd>skin cancer</kwd><kwd>surgery</kwd></kwd-group></article-meta><def-list><title>Abbreviations used</title><def-item><term id="kwrd0060">BCC</term><def><p>basal cell carcinoma</p></def></def-item><def-item><term id="kwrd0070">CLC</term><def><p>complex linear closure</p></def></def-item><def-item><term id="kwrd0080">MMS</term><def><p>Mohs micrographic surgery</p></def></def-item><def-item><term id="kwrd0090">NAC</term><def><p>nipple-areola complex</p></def></def-item><def-item><term id="kwrd0100">NMSC</term><def><p>non&#x02013;melanoma skin cancer</p></def></def-item><def-item><term id="kwrd0110">SCC</term><def><p>squamous cell carcinoma</p></def></def-item><def-item><term id="kwrd0120">UCSD</term><def><p>University of California San Diego</p></def></def-item></def-list></front><body><sec id="sec1"><title>Introduction</title><p id="p0010">Skin cancer is the most frequently diagnosed malignancy, with non&#x02013;melanoma skin cancers (NMSCs)&#x02014;basal cell carcinoma (BCC) and squamous cell carcinoma (SCC)&#x02014;being the most common.<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref><sup>,</sup><xref rid="bib2" ref-type="bibr"><sup>2</sup></xref>&#x000a0;UV exposure, tumor depth, and immunosuppression are major risk factors for NMSC, with chronic sun exposure being the strongest environmental risk factor.<xref rid="bib3" ref-type="bibr">3</xref>, <xref rid="bib4" ref-type="bibr">4</xref>, <xref rid="bib5" ref-type="bibr">5</xref> Although rare, cutaneous malignancy can involve the nipple or areola, and potentially, these tumors can be more aggressive and require specialized care.<xref rid="bib6" ref-type="bibr">6</xref>, <xref rid="bib7" ref-type="bibr">7</xref>, <xref rid="bib8" ref-type="bibr">8</xref> There are limited data available on the epidemiology, risk factors, and optimal management of this condition. Herein, we report the characteristics and surgical outcomes of patients diagnosed with cutaneous malignancy involving the nipple-areola complex (NAC) treated with Mohs micrographic surgery (MMS) at our institution.</p><p id="p0015">For this case series, a retrospective chart review of patients at the University of California San Diego (UCSD) Dermatologic Surgery Unit with NMSC on the NAC between January 1, 2007 and January 1, 2022, was conducted, and 8 patients were identified. Patient and tumor characteristics, surgical details, and adverse outcomes were noted. Adverse outcomes were defined as any complications requiring additional medical or surgical intervention and included skin infections, postoperative bleeding, flap necrosis, graft loss, and wound dehiscence. The surgical margins were determined by taking the difference between the preoperative and postoperative excision dimensions.</p></sec><sec id="sec2"><title>Case series</title><p id="p0020">From January 1, 2007 to January 1, 2022, 8 patients&#x02014;7 males and 1 female&#x02014;underwent surgical interventions at the Department of Dermatology at UCSD for NMSC on the NAC (<xref rid="tbl1" ref-type="table">Table I</xref>). The mean age at diagnosis was 70.7&#x000a0;&#x000b1;&#x000a0;14.5&#x000a0;years. Six patients (75%) had BCC, and 2 patients (25%) had SCC on the NAC. All 8 patients underwent MMS for the excision of cutaneous malignancy involving the NAC. The average preoperative size of the skin cancers was 12.1&#x000a0;&#x000b1;&#x000a0;4.2&#x000a0;mm (range: 5-20&#x000a0;mm), and the average postoperative size was 25.1&#x000a0;&#x000b1;&#x000a0;10.3&#x000a0;mm (range: 12-47&#x000a0;mm). The final surgical margin was 13.0&#x000a0;&#x000b1;&#x000a0;9.8&#x000a0;mm (range: 7-36&#x000a0;mm), and the final surgical length was 5.2&#x000a0;&#x000b1;&#x000a0;17&#x000a0;cm (range: 3.4-8&#x000a0;cm) for linear closures and 1.9&#x000a0;&#x000b1;&#x000a0;1.1&#x000a0;cm<sup>2</sup> (range: 0.5-2.9&#x000a0;cm<sup>2</sup>) for flaps. On average, 2 stages of MMS were needed for histologically clear margins, with a range of 1 to 4 stages. No complications or recurrences were noted over a mean follow-up of approximately 4&#x000a0;years with dermatology.<table-wrap position="float" id="tbl1"><label>Table I</label><caption><p>Characteristics and surgical outcomes of 8 patients diagnosed with cutaneous malignancy involving the nipple or areola at a single institution<xref rid="tbl1fnlowast" ref-type="table-fn">&#x02217;</xref></p></caption><table frame="hsides" rules="groups"><thead><tr><th>Variable</th><th>Case 1</th><th>Case 2</th><th>Case 3</th><th>Case 4</th><th>Case 5</th><th>Case 6</th><th>Case 7</th><th>Case 8</th></tr></thead><tbody><tr><td>Age at diagnosis (years)/sex</td><td>67/M</td><td>44/M</td><td>84/M</td><td>90/M</td><td>66/M</td><td>74/M</td><td>59/M</td><td>75/F</td></tr><tr><td>No. of prior NMSC (<italic>n</italic>)</td><td>5</td><td>0</td><td>8</td><td>15</td><td>12</td><td>5</td><td>1</td><td>0</td></tr><tr><td>History of surgery or radiation on the chest/breast</td><td>No</td><td>No</td><td>No</td><td>No</td><td>No</td><td>No</td><td>No</td><td>Yes (radiation and surgery)</td></tr><tr><td>History of immunosuppression</td><td>No</td><td>No</td><td>No</td><td>No</td><td>No</td><td>No</td><td>No</td><td>Yes<xref rid="tbl1fndagger" ref-type="table-fn">&#x02020;</xref></td></tr><tr><td>History of solid organ malignancy</td><td>No</td><td>No</td><td>No</td><td>No</td><td>No</td><td>No</td><td>No</td><td>Yes</td></tr><tr><td>History of autoimmune disease</td><td>No</td><td>No</td><td>No</td><td>Yes (diabetes)</td><td>No</td><td>No</td><td>No</td><td>Yes (thyroid disease)</td></tr><tr><td>Location of cancer</td><td>Areola</td><td>Areola</td><td>Areola</td><td>Areola&#x000a0;+&#x000a0;nipple</td><td>Areola</td><td>Nipple</td><td>Areola&#x000a0;+&#x000a0;nipple</td><td>Areola</td></tr><tr><td>Type of skin cancer on the breast</td><td>Nodular BCC</td><td>Nodular BCC</td><td>SCC</td><td>SCC</td><td>Multicentric BCC</td><td>Nodular BCC</td><td>Nodular BCC</td><td>Nodular BCC</td></tr><tr><td>Type of surgery</td><td>MMS</td><td>MMS</td><td>MMS</td><td>MMS</td><td>MMS</td><td>MMS</td><td>MMS</td><td>MMS</td></tr><tr><td>Preoperative size (mm)<xref rid="tbl1fnddagger" ref-type="table-fn">&#x02021;</xref></td><td>10</td><td>11</td><td>13</td><td>13</td><td>14</td><td>20</td><td>11</td><td>5</td></tr><tr><td>Postoperative size (mm)<xref rid="tbl1fnsection" ref-type="table-fn">&#x000a7;</xref></td><td>20</td><td>27</td><td>25</td><td>20</td><td>21</td><td>29</td><td>47</td><td>12</td></tr><tr><td>Final surgical margin (mm)</td><td>10</td><td>16</td><td>12</td><td>7</td><td>7</td><td>9</td><td>36</td><td>7</td></tr><tr><td>Final surgical length and type of repair (cm)</td><td>3.4&#x000a0;cm (CLC)</td><td>4.7&#x000a0;cm (CLC)</td><td>6.2&#x000a0;cm (CLC)</td><td>3.6&#x000a0;cm (CLC)</td><td>2.5&#x000a0;cm<sup>2</sup> (advancement flap)</td><td>1.5&#x000a0;cm<sup>2</sup> (C-V transposition flap), 5&#x000a0;cm (CLC)</td><td>0.5&#x000a0;cm<sup>2</sup> (C-V transposition flap), 8&#x000a0;cm (CLC)</td><td>2.9&#x000a0;cm<sup>2</sup> (advancement flap)</td></tr><tr><td>Stages needed for histologically clear margin (n)</td><td>3</td><td>2</td><td>2</td><td>1</td><td>2</td><td>2</td><td>4</td><td>2</td></tr><tr><td>Repair material</td><td>Sutures</td><td>Sutures</td><td>Sutures</td><td>Sutures</td><td>Sutures</td><td>Sutures</td><td>Sutures</td><td>Sutures</td></tr><tr><td>Any complications observed</td><td>No</td><td>No</td><td>No</td><td>No</td><td>No</td><td>No</td><td>No</td><td>No</td></tr><tr><td>Recurrence noted</td><td>No</td><td>No</td><td>No</td><td>No</td><td>No</td><td>No</td><td>No</td><td>No</td></tr><tr><td>Follow-up with dermatology (mo)</td><td>81</td><td>8</td><td>1</td><td>24</td><td>129</td><td>1</td><td>36</td><td>5</td></tr><tr><td>Follow-up at UCSD (mo)</td><td>84</td><td>8</td><td>13</td><td>27</td><td>129</td><td>1</td><td>45</td><td>17</td></tr></tbody></table><table-wrap-foot><fn><p><italic>BCC</italic>, Basal cell carcinoma; <italic>CLC</italic>, complex linear closure; <italic>MMS</italic>, Mohs micrographic surgery; <italic>NMSC</italic>, non&#x02013;melanoma skin cancer; <italic>SCC</italic>, squamous cell carcinoma; <italic>UCSD</italic>, University of California San Diego.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl1fnlowast"><label>&#x02217;</label><p id="ntpara0025">Each patient had 1 unique skin cancer on the breast. No patient had a history of melanoma, transplant, or local trauma to the breast.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl1fndagger"><label>&#x02020;</label><p id="ntpara0030">Patient was previously on chemotherapy for treatment of triple-negative invasive ductal carcinoma of the breast (adriamycin/cytoxan, followed by dose-dense taxol and radiation)</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl1fnddagger"><label>&#x02021;</label><p id="ntpara0035">Greater of the 2 dimensions of the lesion.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl1fnsection"><label>&#x000a7;</label><p id="ntpara0040">Greater of the 2 dimensions of the defect.</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="sec3"><title>Discussion</title><p id="p0025">Cutaneous malignancies involving the NAC may require a multidisciplinary approach, and MMS should be considered as the first-line treatment for these cases. MMS is a surgical technique used to remove skin cancer that spares normal tissue with high cure rate. It is particularly useful for treating skin cancer in areas where tissue sparing is important functionally and/or cosmetically and in areas that are difficult to reconstruct, such as the NAC.</p><p id="p0030">A review of the literature on recurrence rates of NMSC in terms of treatment type revealed 113 previously reported cases of patients diagnosed with BCC on the NAC (<xref rid="tbl2" ref-type="table">Table II</xref>). Of these patients, 6 experienced a recurrence when treated with topical 5-fluorouracil (5-FU, <italic>n</italic>&#x000a0;=&#x000a0;2), excision (<italic>n</italic>&#x000a0;=&#x000a0;3), or a combination of excision and radiation therapy (<italic>n</italic>&#x000a0;=&#x000a0;1), resulting in an overall recurrence rate of 7.9% (6/76). However, the recurrence rate with MMS was 0% (0/17), which is consistent with that in our report (0/6). The recurrence rate with excision in the literature was 5.9% (3/51). Interestingly, 2 patients with superficial BCC underwent treatment with topical 5-FU and both had a recurrence (100%, 2/2), suggesting that 5-FU topical therapy may not have the same efficacy for the treatment of superficial BCC at this site. No patient underwent excision or topical therapy for NMSC of the NAC in our cohort. There are 11 previously reported cases of SCC on the NAC; none of these patients experienced a recurrence with surgical intervention, 1 of which included MMS. This is also in agreement with our report (0/2 recurrence with MMS). However, of the 8 reported cases of SCC in situ on the NAC, a 50% (2/4) recurrence rate was noted after standard excision. One patient treated with photodynamic therapy (1/1) also experienced recurrence of malignancy. None of the patients in our cohort had SCC in situ of the NAC.<table-wrap position="float" id="tbl2"><label>Table II</label><caption><p>Recurrence rates of NMSC of NAC by treatment type, as reported in the literature</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Type of NMSC</th><th>Total No. of patients</th><th>No. of patients with recurrence</th><th>Overall recurrence rate</th><th>Recurrence rate with MMS</th><th>Recurrence rate with excision</th><th>Recurrence rate with topical therapy<xref rid="tbl2fnlowast" ref-type="table-fn">&#x02217;</xref></th></tr></thead><tbody><tr><td>BCC</td><td align="char">113</td><td align="char">6</td><td align="char">7.9% (6/76)</td><td align="char">0% (0/17)<xref rid="tbl2fnddagger" ref-type="table-fn">&#x02021;</xref></td><td align="char">5.9% (3/51)</td><td>100% (2/2)</td></tr><tr><td>SCC<xref rid="tbl2fndagger" ref-type="table-fn">&#x02020;</xref></td><td align="char">11</td><td align="char">0</td><td align="char">0% (0/9)<xref rid="tbl2fnsection" ref-type="table-fn">&#x000a7;</xref></td><td align="char">0% (0/1)</td><td align="char">0% (0/3)<xref rid="tbl2fnVerbar" ref-type="table-fn">&#x02016;</xref></td><td>&#x02013;</td></tr><tr><td>SCC in situ</td><td align="char">8</td><td align="char">3</td><td align="char">50.0% (3/6)<xref rid="tbl2fnsection" ref-type="table-fn">&#x000a7;</xref></td><td>&#x02013;</td><td align="char">50.0% (2/4)<xref rid="tbl2fnsection" ref-type="table-fn">&#x000a7;</xref></td><td>&#x02013;</td></tr></tbody></table><table-wrap-foot><fn><p><italic>BCC</italic>, Basal cell carcinoma; <italic>MMS</italic>, Mohs micrographic surgery; <italic>NAC</italic>, nipple-areola complex; <italic>NMSC</italic>, non&#x02013;melanoma skin cancer; <italic>SCC</italic>, squamous cell carcinoma.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl2fnlowast"><label>&#x02217;</label><p id="ntpara0045">Includes 5-fluorouracil.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl2fndagger"><label>&#x02020;</label><p id="ntpara0050">Includes 1 patient with basosquamous cell carcinoma.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl2fnddagger"><label>&#x02021;</label><p id="ntpara0055">Data missing for 3 patients.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl2fnsection"><label>&#x000a7;</label><p id="ntpara0060">Data missing for 2 patients.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl2fnVerbar"><label>&#x02016;</label><p id="ntpara0065">Data missing for 1 patient.</p></fn></table-wrap-foot></table-wrap></p><p id="p0035">We had previously reported on the use of C-V transposition flaps for defects on the NAC after MMS (<xref rid="fig1" ref-type="fig">Fig 1</xref>).<xref rid="bib9" ref-type="bibr"><sup>9</sup></xref> This approach, which is commonly used in the plastic surgery field for repair after mastectomy, contributes to improved aesthetic outcomes and patient satisfaction by addressing the challenges of NAC reconstruction after MMS, which can be particularly demanding owing to the need for both structural and cosmetic restoration.<fig id="fig1"><label>Fig 1</label><caption><p><bold>A,</bold> Preoperative photograph of BCC of the NAC. <bold>B,</bold> Postoperative defect with no remaining residual tissue of the NAC and C-V flap design in orange. <bold>C,</bold> Postreconstruction of the left side of the nipple after MMS showing reasonable symmetry in location and projection of the reconstructed nipple to the contralateral nipple. <italic>MMS</italic>, Mohs micrographic surgery; <italic>NAC</italic>, nipple-areolar complex. Represented with permission from Dermatologic Surgery.</p></caption><graphic xlink:href="gr1"/></fig></p><p id="p0040">A review of available data of cases of BCC treated with MMS in the literature revealed a mean preoperative size of 17.3&#x000a0;mm, and postoperative size of 25.3&#x000a0;mm, and a final surgical margin of 8&#x000a0;mm achieved over an average of 2 stages (<xref rid="tbl3" ref-type="table">Table III</xref>).&#x000a0;Notably, detailed information was available for only 6 of the 113 cases of BCC. Herein, we contribute 6 cases of BCC of the NAC and 2 cases of SCC of the NAC to the literature, of which there is only 1 prior report. This will lead to a significant increase in the number of reported cases and hopefully help to improve our understanding of these rare conditions.<table-wrap position="float" id="tbl3"><label>Table III</label><caption><p>Surgical details of BCC of NAC treated with MMS, as reported in the literature</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Variable</th><th>Age (y)/Sex</th><th>No. of stages (n)</th><th>Preoperative size (mm)</th><th>Postoperative size (mm)</th><th>Final surgical margin (mm)</th></tr></thead><tbody><tr><td>Case 1</td><td>69/Male</td><td align="char">4</td><td align="char">14</td><td align="char">24</td><td align="char">10</td></tr><tr><td>Case 2</td><td>42/Male</td><td align="char">1</td><td align="char">33</td><td align="char">36</td><td align="char">3</td></tr><tr><td>Case 3</td><td>61/Male</td><td align="char">1</td><td align="char">6</td><td align="char">18</td><td align="char">12</td></tr><tr><td>Case 4</td><td>47/Female</td><td align="char">2</td><td align="char">11</td><td align="char">16</td><td align="char">5</td></tr><tr><td>Case 5</td><td>49/Female</td><td align="char">3</td><td align="char">15</td><td align="char">28</td><td align="char">13</td></tr><tr><td>Case 6</td><td>54/Male</td><td align="char">1</td><td align="char">25</td><td align="char">30</td><td align="char">5</td></tr><tr><td>Mean&#x000a0;&#x000b1;&#x000a0;SD</td><td>53.7&#x000a0;&#x000b1;&#x000a0;9.9</td><td>2.0&#x000a0;&#x000b1;&#x000a0;1.3</td><td>17.3&#x000a0;&#x000b1;&#x000a0;9.9</td><td>25.3&#x000a0;&#x000b1;&#x000a0;7.6</td><td>8.0&#x000a0;&#x000b1;&#x000a0;4.2</td></tr></tbody></table><table-wrap-foot><fn><p><italic>BCC</italic>, Basal cell carcinoma; <italic>MMS</italic>, Mohs micrographic surgery; <italic>NAC</italic>, nipple-areola complex</p></fn></table-wrap-foot></table-wrap></p><p id="p0045">Overall, these findings suggest that MMS is more effective than standard excision in reducing the risk of recurrence of BCC. However, it is important to note that these results are based on a relatively small sample size over a large time frame and that treatments were performed by multiple surgeons at different institutions. Thus, treatment approaches may have varied, and these results may not be generalizable to all patients with NMSC. In addition, given the retrospective nature of the literature review, detailed information regarding surgical margins for the standard excisions were not clearly specified.</p><p id="p0050">Future research should focus on larger sample sizes and incorporate a more comprehensive evaluation of treatment outcomes, including cosmetic outcomes and quality of life, and should aim to better understand the epidemiology, risk factors, and optimal management of this condition.</p><p id="p0055">We conclude that cutaneous malignancy involving the NAC is a rare occurrence, and this case series presented 8 cases of this condition treated with MMS. The review of the literature showed that MMS was a successful surgical treatment for all patients. The final surgical margin was satisfactory, with histologically clear margins achieved after an average of 2 stages, which is in agreement with previously reported cases (<xref rid="tbl3" ref-type="table">Table III</xref>). This study also highlighted the comorbidities and skin cancer characteristics of these patients, which can assist dermatologic surgeons in making treatment decisions.</p></sec><sec sec-type="COI-statement"><title>Conflicts of interest</title><p id="p0060">None disclosed.</p></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="journal" id="sref1"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>S.J.</given-names></name></person-group><article-title>Biology of basal cell carcinoma (Part I)</article-title><source>J Am Acad Dermatol</source><volume>24</volume><year>1991</year><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">1999506</pub-id>
</element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="journal" id="sref2"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>S.J.</given-names></name></person-group><article-title>Biology of basal cell carcinoma (Part II)</article-title><source>J Am Acad Dermatol</source><volume>24</volume><year>1991</year><fpage>161</fpage><lpage>175</lpage><pub-id pub-id-type="pmid">2007661</pub-id>
</element-citation></ref><ref id="bib3"><label>3</label><element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name><surname>Marks</surname><given-names>R.</given-names></name></person-group><article-title>An overview of skin cancers</article-title><source>Cancer</source><volume>75</volume><year>1995</year><fpage>607</fpage><lpage>612</lpage><pub-id pub-id-type="pmid">7804986</pub-id>
</element-citation></ref><ref id="bib4"><label>4</label><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name><surname>Perez</surname><given-names>M.</given-names></name><name><surname>Abisaad</surname><given-names>J.A.</given-names></name><name><surname>Rojas</surname><given-names>K.D.</given-names></name><name><surname>Marchetti</surname><given-names>M.A.</given-names></name><name><surname>Jaimes</surname><given-names>N.</given-names></name></person-group><article-title>Skin cancer: primary, secondary, and tertiary prevention. Part I</article-title><source>J Am Acad Dermatol</source><volume>87</volume><year>2022</year><fpage>255</fpage><lpage>268</lpage><pub-id pub-id-type="pmid">35176397</pub-id>
</element-citation></ref><ref id="bib5"><label>5</label><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name><surname>Rojas</surname><given-names>K.D.</given-names></name><name><surname>Perez</surname><given-names>M.E.</given-names></name><name><surname>Marchetti</surname><given-names>M.A.</given-names></name><name><surname>Nichols</surname><given-names>A.J.</given-names></name><name><surname>Penedo</surname><given-names>F.J.</given-names></name><name><surname>Jaimes</surname><given-names>N.</given-names></name></person-group><article-title>Skin cancer: primary, secondary, and tertiary prevention. Part II</article-title><source>J Am Acad Dermatol</source><volume>87</volume><year>2022</year><fpage>271</fpage><lpage>288</lpage><pub-id pub-id-type="pmid">35176398</pub-id>
</element-citation></ref><ref id="bib6"><label>6</label><element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><name><surname>Shertz</surname><given-names>W.T.</given-names></name><name><surname>Balogh</surname><given-names>K.</given-names></name></person-group><article-title>Metastasizing basal cell carcinoma of the nipple</article-title><source>Arch Pathol Lab Med</source><volume>110</volume><year>1986</year><fpage>761</fpage><lpage>762</lpage><pub-id pub-id-type="pmid">3755334</pub-id>
</element-citation></ref><ref id="bib7"><label>7</label><element-citation publication-type="journal" id="sref7"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>P.J.</given-names></name><name><surname>Milch</surname><given-names>J.M.</given-names></name><name><surname>Hivnor</surname><given-names>C.M.</given-names></name></person-group><article-title>Pigmented basal cell carcinoma of the nipple: a case report and review of the literature</article-title><source>Cutis</source><volume>92</volume><year>2013</year><fpage>253</fpage><lpage>257</lpage><pub-id pub-id-type="pmid">24343213</pub-id>
</element-citation></ref><ref id="bib8"><label>8</label><element-citation publication-type="journal" id="sref8"><person-group person-group-type="author"><name><surname>Trignano</surname><given-names>E.</given-names></name><name><surname>Manzo</surname><given-names>M.J.</given-names></name><name><surname>Paliogiannis</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Basal cell carcinoma of the nipple-areola complex: report of a case and literature review</article-title><source>Ann Ital Chir</source><volume>84</volume><year>2013</year><object-id pub-id-type="publisher-id">S2239253X13021749</object-id></element-citation></ref><ref id="bib9"><label>9</label><element-citation publication-type="journal" id="sref9"><person-group person-group-type="author"><name><surname>Chow</surname><given-names>M.</given-names></name><name><surname>Sohn</surname><given-names>G.</given-names></name><name><surname>Brian Jiang</surname><given-names>S.I.</given-names></name></person-group><article-title>How We Do It: C-V Transposition flap for reconstruction of the nipple-areolar complex after Mohs surgery</article-title><source>Dermatol Surg</source><volume>47</volume><year>2021</year><fpage>539</fpage><lpage>541</lpage><pub-id pub-id-type="pmid">32205750</pub-id>
</element-citation></ref></ref-list><fn-group><fn id="d35e733"><p id="ntpara0010">Funding sources: None.</p></fn><fn id="d35e736"><p id="ntpara0015">Patient consent: All patients gave consent for their medical information and photographs to be published in print and online and with the understanding that this information may be publicly available.</p></fn><fn id="d35e739"><p id="ntpara0020">IRB approval status: Reviewed and approved by University of California San Diego IRB (IRB #805200).</p></fn></fn-group></back></article>
